RTP Mobile Logo
Biomarker Analysis and the Implications for the Treatment of Non-Small Cell Lung Cancer
Released December 2017

Featuring interviews with Drs Gregory J Riely and Marc Ladanyi. (Audio Content)

CE Disclosures and Faculty Information

    Recent developments have led to an explosion in lung cancer genetic and biologic knowledge, but the integration of anti-PD-1/PD-L1 checkpoint inhibitors into treatment and the evolution of targeted therapy have complicated decision-making for clinicians caring for patients with metastatic non-small cell lung cancer (NSCLC).

    To assist medical oncologists as they think through the complex management of NSCLC, this program features the perspectives of a lung cancer clinical oncology investigator and a pathologist on the results of a patterns of care survey of 25 thoracic oncology experts documenting the current state of biomarker analysis and the related implications for treatment. Upon completion of this CME activity, medical oncologists should be able to formulate an up-to-date and more complete approach to the care of patients with lung cancer.


    • Analyze the effects of tumor histology, genetic alterations and PD-L1 tumor proportion score on the practice patterns of clinical investigators in the management of NSCLC.
    • Recognize the utility and limitations of multiplex and next-generation sequencing platforms, and determine their clinical application for patients with NSCLC.
    • Review available research data on the effectiveness of approved EGFR tyrosine kinase inhibitors (TKIs) in patients with various EGFR mutations, and use this information to guide first-line treatment decision-making.
    • Describe mechanisms of tumor resistance to EGFR TKIs, and understand the therapeutic options for patients whose disease progresses on first-line EGFR therapy.
    • Describe available and emerging data on the efficacy of anti-PD-1/PD-L1 antibodies in NSCLC, and consider this information when counseling patients regarding treatment options. 
    • Assess new oncogenic pathways mediating the growth of unique NSCLC tumor subsets, and recall emerging data with experimental agents exploiting these targets.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity contains an audio component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr RielyConsulting Agreement: Genentech BioOncology; Contracted Research: Ariad Pharmaceuticals Inc, Astellas Pharma Global Development Inc, Novartis, Pfizer Inc. Dr LadanyiContracted Research: AstraZeneca Pharmaceuticals LP, Loxo Oncology.

    EDITOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP. 

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: December 2017
    Expiration date: December 2018

Acknowledge and close

Listen to audio:
Biomarker Analysis and the Implications for the Treatment of Non-Small Cell Lung Cancer
Released December 2017

Featuring interviews with Drs Gregory J Riely and Marc Ladanyi. (Audio Content)

Read print: